Erasca, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Erasca, Inc. (ERAS) holds an ST Score of 48.4 out of 100 (C+), with its strongest factor being Momentum (B+) and its weakest Profitability (C-). Analysts rate ERAS Buy across 11 ratings with a $22.50 average price target (+0.5% vs the current $15.04).
- Strongest
- MomentumB+
- Weakest
- ProfitabilityC-
All factor grades
- MomentumB+
- ForecastB
- ValuationB-
- GrowthB-
- Financial StrengthC+
- ProfitabilityC-
- Piotroski1/9
Contact
ERAS stock: frequently asked questions
What is ERAS's ST Score?
Erasca, Inc. (ERAS) has an ST Score of 48.4 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ERAS a buy, sell, or hold?
Wall Street's consensus rating on ERAS is Buy based on 11 analyst ratings. Our own ST Score grades it C+ (48.4/100). This is data, not investment advice — always do your own research.
What is ERAS's valuation grade?
Erasca, Inc. (ERAS) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ERAS's growth grade?
Erasca, Inc. (ERAS) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ERAS's profitability grade?
Erasca, Inc. (ERAS) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ERAS's financial strength grade?
Erasca, Inc. (ERAS) earns a financial strength grade of C+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ERAS?
The average analyst price target for Erasca, Inc. (ERAS) is $22.50 from 11 analysts, which is +0.5% versus the recent price of $15.04.
What is ERAS's Piotroski score?
Erasca, Inc. (ERAS) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.